-
公开(公告)号:US20060009454A1
公开(公告)日:2006-01-12
申请号:US11152650
申请日:2005-06-14
申请人: Zhen-wei Cai , Louis Lombardo , Rajeev Bhide , Ligang Qian , Donna Wei , Stephanie Barbosa
发明人: Zhen-wei Cai , Louis Lombardo , Rajeev Bhide , Ligang Qian , Donna Wei , Stephanie Barbosa
IPC分类号: A61K31/53 , C07D487/04
CPC分类号: C07D487/04
摘要: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
-
公开(公告)号:US20070299075A1
公开(公告)日:2007-12-27
申请号:US11832976
申请日:2007-08-02
申请人: Rajeev Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
发明人: Rajeev Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
IPC分类号: A61K31/4196 , A61P43/00 , C07D253/06
CPC分类号: C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译: 本发明提供式I化合物及其药学上可接受的盐。式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性,从而使其用作抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
公开(公告)号:US20050124621A1
公开(公告)日:2005-06-09
申请号:US11035248
申请日:2005-01-13
申请人: Rajeev Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
发明人: Rajeev Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
IPC分类号: A61K31/53 , A61K31/5377 , A61K31/541 , A61K31/662 , A61K45/00 , A61K45/06 , A61P1/04 , A61P1/16 , A61P3/04 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/06 , A61P9/08 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/08 , A61P13/10 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/00 , A61P19/02 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/16 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/10 , A61P31/12 , A61P31/18 , A61P31/22 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61P43/00 , C07D487/02 , C07D487/04 , C07F9/6561
CPC分类号: C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译: 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性,从而使其成为抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
公开(公告)号:US20060135576A1
公开(公告)日:2006-06-22
申请号:US11349767
申请日:2006-02-08
申请人: Robert Borzilleri , Rajeev Bhide , John Tokarski , Peter Zheng , Ligang Qian , Zhen-Wei Cai
发明人: Robert Borzilleri , Rajeev Bhide , John Tokarski , Peter Zheng , Ligang Qian , Zhen-Wei Cai
IPC分类号: A61K31/426 , A61K31/421
CPC分类号: C07D277/42 , C07D417/12 , C07D417/14
摘要: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
-
公开(公告)号:US20060128709A1
公开(公告)日:2006-06-15
申请号:US11345845
申请日:2006-02-02
申请人: John Hunt , Rajeev Bhide , Robert Borzilleri , Ligang Qian
发明人: John Hunt , Rajeev Bhide , Robert Borzilleri , Ligang Qian
IPC分类号: A61K31/53 , C07D487/04
CPC分类号: C07D519/00 , C07D487/04
摘要: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
-
公开(公告)号:US20060004007A1
公开(公告)日:2006-01-05
申请号:US11190412
申请日:2005-07-27
申请人: John Hunt , Rajeev Bhide , Robert Borzilleri , Ligang Qian
发明人: John Hunt , Rajeev Bhide , Robert Borzilleri , Ligang Qian
IPC分类号: A61K31/53
CPC分类号: C07D519/00 , C07D487/04
摘要: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
-
公开(公告)号:US20060058304A1
公开(公告)日:2006-03-16
申请号:US11214267
申请日:2005-08-29
申请人: Rajeev Bhide , Rejean Ruel , Carl Thibault , Alexandre L'Heureux
发明人: Rajeev Bhide , Rejean Ruel , Carl Thibault , Alexandre L'Heureux
IPC分类号: A61K31/53 , C07D487/04
CPC分类号: C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译: 本发明提供式I化合物,
-
公开(公告)号:US6011029A
公开(公告)日:2000-01-04
申请号:US802329
申请日:1997-02-20
申请人: Charles Z. Ding , Soong-Hoon Kim , John T. Hunt , Toomas Mitt , Rajeev Bhide , Katerina Leftheris
发明人: Charles Z. Ding , Soong-Hoon Kim , John T. Hunt , Toomas Mitt , Rajeev Bhide , Katerina Leftheris
IPC分类号: C07D401/14 , A61K31/00 , A61K31/35 , A61K31/4178 , A61K31/495 , A61K31/498 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/675 , A61P35/00 , A61P43/00 , C07D20060101 , C07D243/14 , C07D245/06 , C07D401/04 , C07D401/10 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07D453/02 , C07D471/04 , C07D473/00 , C07D487/04 , C07D491/044 , C07D491/048 , C07D495/04 , C07D497/04 , C07D513/04 , C07F9/645 , C07D243/24
CPC分类号: C07D243/14 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D473/00 , C07D487/04 , C07D495/04
摘要: The present invention comprises benzodiazepine compounds having farnesyl transferase inhibitory activity.
摘要翻译: 本发明包括具有法呢基转移酶抑制活性的苯并二氮杂类化合物。
-
公开(公告)号:US20050234060A1
公开(公告)日:2005-10-20
申请号:US11157890
申请日:2005-06-21
申请人: Rajeev Bhide , Robert Borzilleri
发明人: Rajeev Bhide , Robert Borzilleri
CPC分类号: C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
-
公开(公告)号:US06455523B1
公开(公告)日:2002-09-24
申请号:US09374210
申请日:1999-08-13
申请人: Charles Z. Ding , Soong-Hoon Kim , John T. Hunt , Toomas Mitt , Rajeev Bhide , Katerina Leftheris
发明人: Charles Z. Ding , Soong-Hoon Kim , John T. Hunt , Toomas Mitt , Rajeev Bhide , Katerina Leftheris
IPC分类号: A61K3155
CPC分类号: C07D243/14 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D473/00 , C07D487/04 , C07D495/04
摘要: Inhibition of farnesyl transferase, which is an enzyme involved in ras ocogene expression, is effected by compounds of the formulas their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof inhibit farnesyl protein transferase which is an enzyme involved in ras oncogene expression. In formulas I-IV and throughout their specification, the above symbols are defined as follows: m, n, r, s and t are 0 or 1; p is 0, 1 or 2; V, W and X are selected from the group consisting of oxygen, hydrogen, R1, R2 or R3; Z and Y are selected from the group consisting of CHR9, SO2, SO3, CO, CO2, O, NR10, So2NR11, CONR12, or Z may be absent; R6, R7, R9, R10, R11, R12 R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R24, R25, R26, R27, R28, R29, R30, R31, R32,R33, R34, R35, R36, R37, and R38 are selected from the group consisting of hydrogen, lower alkyl, substituted alkyl, aryl or substituted aryl; R4, R5 are selected from the group consisting of hydrogen, halo, nitro, cyano and U-R23; U is selected from the group consisting of sulfur, oxygen, NR24, CO, SO, SO2, CO2, NR25CO2, NR26CONR27, NR28SO2, NR29SO2NR30, SO2NR31, NR32CO, CONR33, PO2R34 and PO3R35 or U is absent; R1, R2, and R3 are selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, cycloalkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, cyano, carboxy, carbamyl (e.g. CONH2) or substituted carbamyl further selected from CONH alkyl, CONH aryl, CONH aralkyl or cases where there are two substituents on the nitrogen selected from alkyl, aryl or aralkyl; R8 and R23 are selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, cycloalkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo; Any two of R1, R2, and R3 can be joined to form a cycloalkyl group; R, S and T are selected from the group consisting of CH2, CO and CH(CH2)pQ wherein Q is NR36R37, OR38, or CN; and A, B, C and D are carbon, oxygen, sulfur or nitrogen. with the provisos that 1. When m is zero then V and W are not both oxygen or 2 W and X together can be oxygen only if Z is either absent, O, NR10, in formulas I and II, and V and X together can be oxygen only if Y is O, NR10, in formulas III and IV or 3. R23 may be hydrogen except when U is SO, SO2, NR25CO2 or NR28SO2, or 4. R8 may be hydrogen except when Z is SO2, CO2, or
-
-
-
-
-
-
-
-
-